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Immune reconstitution syndrome following HAART in hu-
man immunodeficiency virus (HIV)–infected patients is
characterized by inflammatory worsening of organ functions
despite improvement in HIV surrogate markers of HIV in-
fection. We describe a patient with miliary tuberculosis and
urinary shedding of acid fast bacilli who developed acute
renal failure 8 weeks after initiation of antituberculosis ther-
apy and 6 weeks after initiation of HAART. The diagnostic
workup and further course of disease implicated immune
reconstitution syndrome as the cause of acute renal failure.
Acute renal failure (ARF) is frequently encountered in patients
with HIV infection [1,2]. In a recent retrospective study of 92
HIV-infected patients with ARF admitted to a nephrology unit
[3], at least 10 different entities were diagnosed: hemolytic-
uremic syndrome (in 35% of patients), acute tubular necrosis
(in 26%), HIV-associated nephropathy (in 15%), acute inter-
stitial nephritis (in 2%), obstructive renal failure due to lym-
phoma and drug- and paraprotein-mediated causes (in 17%),
and various forms of glomerulonephritis (in 4%). In contrast
to ARF due to prerenal and postrenal causes, renal forms of
ARF in HIV-infected patients are often related to HIV-mediated
viral or immunological disease, or to treatment-related toxicity,
both of which have changed since the introduction of HAART
[1–3].
Case report. A 58-year-old male was hospitalized because
of fever and weight loss of 110 kg in the 3 months prior to
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hospital admission. HIV infection (CD4 cell count, 69 cells/
mL; virus load, 1,247,786 copies/mL) and miliary tuberculosis
was diagnosed. Acid-fast bacteria were seen in bronchoalveolar
lavage fluid and in urine specimens. Mycobacterium tuberculosis
was identified by culture and specific PCR. The patient was
initially treated with standard doses of 4 antituberculosis agents
(isoniazid, rifampicin, pyrazinamid, and ethambutol). Primary
prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX)
3 times weekly was started. After 2 weeks, rifampicin was re-
placed with rifabutin at a reduced dosage of 150 mg q.o.d., at
the time when HAART was initiated (zidovudine, lamivudine,
and lopinavir/ritonavir) (figure 1). Drug-susceptibility testing
of the Mycobacterium tuberculosis isolate revealed no resistance,
and a 3-drug regimen consisting of isoniazid, pyrazinamid, and
rifabutin was administered. The clinical condition improved,
and the patient was referred to a rehabilitation clinic.
However, after 2 months, ARF developed with rising serum
creatinine concentrations of 4.89 mg/dL (433 mmol/L), and the
patient was readmitted to the hospital. Overall, the clinical
status had improved. There was no fever, coughing, or lymph-
adenopathy. Macrocytic hyperchromic anemia was found, with
a hemoglobin concentration of 9 g/dL. The C-reactive protein
level measured 95 mg/L (normal range, !5 mg/L), increasing
to 142 mg/L. The HIV load had decreased by 4 log10, to 104
copies/mL, and the CD4 cell count had increased to 82 cells/
mL. Urine analysis showed mild proteinuria with a tubuloin-
terstitial pattern (urine protein to creatinine concentration of
53 mg/mmol, and ratios of a-1 microglobulin to creatinine and
retinol-binding protein to creatinine increased by 31-fold and
46-fold, respectively) in addition to few granular casts and few
leukocytes. Serial CT of the chest showed newly accentuated
pulmonary infiltrates. Bronchoscopy and bronchoalveolar lav-
age were performed and revealed lymphocytosis, but yielded
negative results for a range of infectious agents, including My-
cobacterium tuberculosis, Mycoplasma and Chlamydia species,
cytomegalovirus, and bacterial pathogens. A renal biopsy was
performed. Histologic examination showed severe, nondestruc-
tive, granulomatous nephritis with interstitial infiltrates (figure
2). Iimmunohistochemical analysis was negative for comple-
ments C3 and C5b-9, fibrin, IgA, IgM, and IgG (not shown).
The diagnosis of immune reconstitution syndrome with
manifestations in the lungs and kidneys was made 2 months
after initiation of HAART, which effectively suppressed HIV
replication and resulted in improved CD4 cell counts. Pred-
nisone was administered at a dosage of 1 mg/kg for 2 weeks
with a tapering dosage (figure 1). HAART was continued, but
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Figure 1. Time course of laboratory values and drug treatment in 2002 and 2003 for an HIV-infected patient with acute renal failure. Left Y-axis:
Dotted line, Serum creatinine concentration, mmol/L; squares, C- reactive protein levels, mg/L ; and circles, CD4 cell counts, cells/mL. Right Y-axis:
Triangles, HIV-1 viral load, log10/mL. The treatment administered is shown on top: zidovudine (AZT), lamivudine (3TC), lopinavir/ritonavir (LPV/r), stavudine
(d4T), trimethoprim-sulfamethoxazole primary prophylaxis (TMP-SMX), isoniazid (INH), rifabutin (RFB), pyrazinamide (PZA), ethambutol (ETB), prednisolone
(PRE, dosage in mg) and pentacarinate (PCT).
stavudine was substituted for zidovudine because of anemia.
TMP-SMX therapy was discontinued, and antituberculosis
therapy was continued as a 2-drug regimen of isoniazid and
rifabutin at the same dosages. C-reactive protein levels nor-
malized and renal function improved, with serum creatinine
concentrations of ∼1.7 mg/dL (145 mmol/L) within 10 days
(figure 1). Primary prophylaxis with pentacarinate was started
but not tolerated, and TMP/SMX prophylaxis was reinitiated
and well tolerated. The CD4 cell count increased to 174 cells/
mL but then decreased slightly, and the HIV load remained
undetectable (!20 copies/mL). After 1 year, the patient re-
mained healthy while receiving HAART and TMP-SMX, and
antituberculosis treatment could be discontinued.
Discussion. The inflammatory syndrome elicited by im-
proving immune response to mycobacterial antigens has been
described in patients with AIDS as early as 1992, at a time when
only zidovudine was available for use against HIV [4]. Since
the introduction of HAART, paradoxical clinical worsening is
increasingly reported, most likely reflecting the more efficient
immune recovery. The immune responses were directed against
a range of antigens derived from infectious agents, such as
cytomegalovirus, hepatitis viruses, Histoplasma species, poly-
omaviruses JC and BK, and Cryptococcus neoformans [5–7], but
also from noninfectious antigens [8, 6]. The latter observation
supports the notion that the primary pathogenic element of
immune reconstitution syndrome is a severe inflammatory re-
sponse directed against antigens but not necessarily against on-
going infections. However, this distinction may be difficult to
make at times. Apart from frequent manifestations in lungs
[9–11], immune reconstitution syndrome directed against M.
tuberculosis may affect the lymph nodes, CNS, liver, testicles,
and gut [12–14]. In our patient, ARF occurred concurrently
with radiologically documented signs of pulmonary worsening
and increasing levels of C-reactive protein, and cultures re-
mained negative for M. tuberculosis . The main differential di-
agnosis of ARF in our patient included drug toxicity caused by
TMP-SMX and/or ritonavir. However, in contrast to previous
reports, the ritonavir dosage was set as required for “boosting”
protease inhibitor activity, and this therapy was safely continued
for our patient. Similarly, TMP-SMX prophylaxis was safely
reintroduced (figure 1). Ethambutol might represent be a rare
cause of interstitial nephritis, and this cause cannot be ruled
out with certainty. However, there were no signs of neural
toxicity or optic neuritis in our patient.
The initial identification of M. tuberculosis in the urine in-
dicated a disseminated infection that involved the kidneys. The
identification of ARF with granulomatous inflammation by re-
nal biopsy concurrent with systemic inflammatory signs and
paradoxical worsening of pulmonary infiltrates supports the
diagnosis of immune reconstitution syndrome, despite only
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Figure 2. Micrographs of a renal biopsy specimen showing granulomatous nephritis ( top, hematoxilin-eosin stain; original magnification 5) with
nonnecrotizing epitheloid granuloma and faint fibrosis (bottom, sirius stain; original magnification 200).
modest increases in the CD4 cell count in the peripheral blood.
It is remarkable that immune reconstitution syndrome has been
observed in HIV-infected patients with substantially lesser in-
creases in CD4 cell counts in the peripheral blood [5]. The
pathophysiology of the immune reconstitution syndrome is still
incompletely understood, but host- and antigen-specific factors
may play a role, in addition to specific CD4 cell responses and,
possibly, CD4 cell redistribution in tissue. However, the in-
creasing incidence of immune reconstitution syndrome follow-
ing the introduction of HAART suggests that suppression of
HIV replication is a significant, but not a sufficient, factor. In
our patient, a substantial decrease in HIV load (4 log10) was
noted within only 6 weeks. In summary, immune reconsti-
tution syndrome should be considered as a cause of ARF after
initiation of HAART in patients who have AIDS and renally
disseminated antigens, as documented here for miliary
tuberculosis.
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